Business
AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care
The ALPHA-PE Research Fund Supports Independent, Physician-Led Studies to Advance Real-World PE Evidence LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc.
About this update from Angiodynamics, Inc.
[{"type":"text","content":"\nThe ALPHA-PE Research Fund Supports Independent, Physician-Led Studies to Advance Real-World PE Evidence\n\n\n LATHAM, N.Y.--(BUSINESS WIRE)--\nAngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, and The PERT Consortium®, a leading multidisciplinary organization dedicated to improving pulmonary embolism (PE) care, today announced the launch of the ALPHA-PE Research Fund, an investigator-led initiative supporting independent PE research.\n\n\nPulmonary embolism affects approximately one in 1,000 people annually1. It is estimated to contribute to more than 50,000 deaths each year in the United States,2 underscoring the need for continued clinical research and innovation.\n\n\nThe ALPHA-PE Research Fund is designed to support independent, physician-led research addressing critical evidence gaps in pulmonary embolism care, where a lack of real-world data often limits clinical decision-making. By enabling investigator-driven studies, the program aims to accelerate the generation of clinically relevant evidence to inform care delivery and advance understanding of PE management.\n\n\nAwards ranging from $50,000 to $750,000 over one to three years will be distributed, empowering both established and emerging investigators to pursue data-driven research focused on patient outcomes, workflow optimization, or novel therapeutic approaches with the potential to improve real-world PE care.\n\n\n“This initiative reflects our commitment to supporting the cardiovascular community in closing critical data gaps in pulmonary embolism care,” said Laura Piccinini, Senior Vice President and General Manager, Cardiovascular & International at AngioDynamics. “By supporting investigator-led studies, we strengthen the evidence base for approaches that can improve patient outcomes and advance the standard of care.”\n\n\n“Independent, physician-led research plays a critical role in generating real-world insight in treating pulmonary embolism,” said Juan Carlos Serna, Senior Vice President of Scientific & Clinical Affairs at AngioDynamics. “The ALPHA-PE Research Fund is designed to foster science-driven collaboration that advances understanding and care for patients.”\n\n\nIn...